Literature DB >> 22475108

Platelet-rich plasma improves wound healing in multiple myeloma bisphosphonate-associated osteonecrosis of the jaw patients.

V Coviello, F Peluso, S Z Dehkhargani, F Verdugo, L Raffaelli, P F Manicone, A D' Addona.   

Abstract

Bisphosphonates are drugs used to treat various metabolic and malignant bone diseases. In the past 10 years intravenous bisphosphonates have been associated with increased risk of osteonecrosis of the jaw (ONJ). The aim of the present study is to evaluate platelet-rich plasma (PRP) wound healing benefits in multiple myeloma (MM) patients who developed ONJ after surgical tooth extraction. The study included 7 patients, 2 males and 5 females. All individuals had been taking zoledronate or pamidronate followed by zoledronate for an average of 5 years. Four subjects had only standard surgical debridement and sequestrectomy to treat the ONJ and three had additional autologous PRP. The patients were followed-up for 3 months. The use of PRP to enhance wound healing and reduce bone exposure seems to be a good treatment protocol in ONJ MM subjects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475108

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  8 in total

1.  The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Authors:  Meltem Ozden Yüce; Emine Adalı; Gözde Işık
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573

Review 2.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

3.  Conservative Surgical Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw with Er,Cr:YSGG Laser and Platelet-Rich Plasma: A Longitudinal Study.

Authors:  Rodolfo Mauceri; Vera Panzarella; Laura Maniscalco; Alberto Bedogni; Maria Ester Licata; Antonino Albanese; Francesca Toia; Enzo Maria Giuseppe Cumbo; Giuseppina Mazzola; Olga Di Fede; Giuseppina Campisi
Journal:  Biomed Res Int       Date:  2018-08-19       Impact factor: 3.411

4.  Application of Autologous Platelet-Rich Plasma on Tooth Extraction Site Prevents Occurence of Medication-Related Osteonecrosis of the Jaws in Rats.

Authors:  Luan Felipe Toro; João Martins de Mello-Neto; Fernanda Furuse Ventura Dos Santos; Letícia Chaves Ferreira; Cristian Statkievicz; Luciano Tavares Ângelo Cintra; João Paulo Mardegan Issa; Rita Cássia Menegati Dornelles; Juliano Milanezi de Almeida; Maria José Hitomi Nagata; Valdir Gouveia Garcia; Leticia Helena Theodoro; Cláudio Aparecido Casatti; Edilson Ervolino
Journal:  Sci Rep       Date:  2019-01-10       Impact factor: 4.379

5.  Assessment of Knowledge, Awareness, and Perception of Platelet-Rich Plasma among Oral Surgeons.

Authors:  Sujithraj Stephen; Selvakumar Ramar; Chinnaiah Rajendran; Nirmala Mrugesh Devar; I Bevin Shaga; Revathi Somasundaram; Bhuvaneswari Mani; Nagappan Nagappan; S M M Moulvi
Journal:  J Pharm Bioallied Sci       Date:  2022-07-13

6.  Platelet-rich plasma (PRP) in dental and oral surgery: from the wound healing to bone regeneration.

Authors:  Antonino Albanese; Maria E Licata; Bianca Polizzi; Giuseppina Campisi
Journal:  Immun Ageing       Date:  2013-06-13       Impact factor: 6.400

Review 7.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06

Review 8.  Bone substitutes: a review of their characteristics, clinical use, and perspectives for large bone defects management.

Authors:  Gabriel Fernandez de Grado; Laetitia Keller; Ysia Idoux-Gillet; Quentin Wagner; Anne-Marie Musset; Nadia Benkirane-Jessel; Fabien Bornert; Damien Offner
Journal:  J Tissue Eng       Date:  2018-06-04       Impact factor: 7.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.